老年多发性骨髓瘤患者诊断后早期死亡及其竞争风险特征:一项基于人群的回顾性研究OA
Early mortality and competing risk patterns after diagnosis in elderly patients with multiple myeloma:A population-based retro-spective study
目的:探讨老年多发性骨髓瘤(MM)患者诊断后早期病因特异性死亡及竞争性死亡的特征,并评估不同年龄组间的死亡风险差异.方法:基于美国监测、流行病学与结局(SEER)数据库,纳入2000-2022年诊断时年龄≥65岁的MM患者,按年龄分为65~74岁、75~84岁和≥85岁三组.采用累积发生函数估计诊断后3、6及12个月的死亡风险,Gray检验比较组间差异,并运用Fine-Gray模型评估年龄与MM相关死亡风险的关联.结果:共纳入55 049例符合条件的老年MM患者.诊断后3个月,65~74岁、75~84岁和≥85岁组MM相关死亡的累积发生率分别为8.3%、15.1%和25.3%;6 个月时,分别为11.3%、19.8%和32.6%;12 个月时,分别为16.1%、26.2%和40.2%,呈明显的年龄梯度.诊断后12个月,三组其他原因死亡的累积发生率分别为6.4%、9.3%和14.4%,均低于同期MM相关死亡.Gray检验显示,不同年龄组间MM 相关死亡及其他原因死亡的累积发生率差异均有统计学意义.多因素 Fine-Gray 分析显示,以65~74岁组为参照,75~84岁组MM相关死亡的亚分布风险升高36%(sHR=1.36,95%CI:1.32-1.39,P<0.001),≥85岁组升高79%(s HR=1.79,95%CI:1.72-1.86,P<0.001).排除种族信息未知患者及化疗情况后的敏感性分析结果与主分析一致.结论:老年 MM患者诊断后早期MM相关死亡风险较高,并随年龄增加呈明显梯度升高.高龄与 MM 相关死亡风险升高独立相关,尤其≥85岁患者的早期死亡负担突出.加强老年MM患者的早期风险评估及适应性干预策略可能有助于降低早期死亡.
Objective:To characterize early multiple myeloma(MM)-specific mortality and competing-cause mortality after diagnosis in elderly patients with MM,and to evaluate differences in mortality risk across age groups.Methods:Using data from the Surveillance,Epi-demiology,and End Results(SEER)database,we included patients diagnosed with MM between 2000 and 2022 who were aged≥65 years at diagnosis.Patients were stratified into three age groups:65-74,75-84,and≥85 years.Cumulative incidence functions were used to esti-mate mortality at 3,6,and 12 months after diagnosis.Differences across age groups were assessed using Gray's test,and Fine-Gray models were applied to evaluate the association between age and MM-specific mortality.Results:A total of 55,049 eligible elderly patients with MM were included.At 3 months after diagnosis,the cumulative incidences of MM-specific death were 8.3%,15.1%,and 25.3%in patients aged 65-74,75-84,and≥85 years,respectively;corresponding estimates at 6 months were 11.3%,19.8%,and 32.6%,and at 12 months were 16.1%,26.2%,and 40.2%,demonstrating a clear age-related gradient.At 12 months,the cumulative incidences of other-cause death were 6.4%,9.3%,and 14.4%,respectively,all lower than the corresponding incidences of MM-specific death.Gray′s tests showed statistically sig-nificant differences across age groups for both MM-specific and other-cause mortality.In multivariable Fine-Gray analyses,compared with patients aged 65-74 years,the subdistribution hazard of MM-specific death was 36%higher in those aged 75-84 years(sHR=1.36,95%CI:1.32-1.39,P<0.001)and 79%higher in those aged≥85 years(sHR=1.79,95%CI:1.72-1.86,P<0.001).Sensitivity analyses after excluding patients with unknown racial information and those receiving chemotherapy yielded results consistent with the primary analysis.Conclusion:Elderly patients with MM experience a substantial risk of early MM-specific death after diagnosis,with a pronounced increase across advancing age groups.Advanced age is independently associated with a higher risk of MM-specific mortality,and the early mortality burden is particularly marked among patients aged≥85 years.Strengthening early risk assessment and age-adapted interventions may help reduce early mortality in elderly patients with MM.
乔瑞丽;张淑玲;范晟煊;赵龙;张豪
兰州大学第一医院,甘肃 兰州 730000兰州大学第一医院,甘肃 兰州 730000兰州大学第一医院,甘肃 兰州 730000兰州大学第一医院,甘肃 兰州 730000兰州大学第一医院,甘肃 兰州 730000
医药卫生
多发性骨髓瘤老年患者早期死亡竞争风险累积发生函数Fine-Gray模型
multiple myelomaelderly patientsearly mortalitycompeting riskscumulative incidence functionFine Gray model
《甘肃医药》 2026 (6)
502-506,5
评论